HR Execs on the Move

Engrail Therapeutics

www.engrail.com

 
Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.engrail.com
  • 12750 High Bluff Drive Suite 190
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details
Vikram Sudarsan
President and Chief Executive Officer Profile

Similar Companies

Spectrum Plastics Group

We are leaders in medical plastics design, development & manufacture, with over 2,000 employees, and 20 manufacturing locations worldwide.

Hikma Pharmaceuticals

At Hikma we put better health within reach, every day. We create high quality medicines, and we make them accessible and affordable to the people who need them.

Iconix Biosciences

Iconix Biosciences is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kentucky Counseling Center

We provide counseling, psychiatry, and targeted case management for children and adults without the long wait times throughout Kentucky. Discover our services today.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.